Lipolytic methods
Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
1. A method of administration to subcutaneous tissue for reducing regional fat in a subject, the method comprising contacting the subcutaneous tissue of the subject with a pharmaceutically effective amount of a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt, solvate, or combinations thereof in an amount that is up to about 250 micrograms per week, provided that the contacting is less frequently than once per day, and wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist comprises at least one of salmeterol, formoterol, bambuterol, or any salt, solvate, or any combination thereof.
2. The method of claim 1 , provided that the lipophilic long-acting selective beta-2 adrenergic receptor agonist comprises salmeterol xinafoate.
3. The method of claim 1 , provided that the lipophilic long-acting selective beta-2 adrenergic receptor agonist comprises formoterol fumarate.
4. The method of claim 1 , provided that the contacting comprises administration by subcutaneous injection.
5. The method of claim 2 , provided that the contacting comprises administration by subcutaneous injection.
6. The method of claim 1 , provided that the contacting comprises transdermal administration.
7. The method of claim 2 , provided that the contacting comprises transdermal administration.
8. The method of claim 1 , provided that the lipophilic long-acting selective beta-2 agonist comprises salmeterol, or any salt, solvate, or any combination thereof, and the pharmaceutically effective amount is up to about 100 micrograms per day contacted.
9. The method of claim 1 , provided that the lipophilic long-acting selective beta-2 agonist comprises formoterol, or any salt, solvate, or combination thereof, and the pharmaceutically effective amount is up to about 50 micrograms per day contacted.
10. The method of claim 1 , provided that at least one of the lipophilic long-acting selective beta-2 adrenergic receptor agonist is administered by single needle injection or by needleless injection.
11. The method of claim 1 , provided that the subcutaneous tissue comprises periorbital fat, submental fat, abdominal fat, waist fat, hip fat, or thigh fat.
12. The method of claim 2 , provided that the administration is subcutaneously or transdermally.
13. A method of reducing regional fat accumulation in a subject comprising administering to the regional fat accumulation a composition, by subcutaneous injection or transdermal administration, that comprises a lipophilic long-acting selective beta-2 agonist, or a salt, solvate, or combinations thereof that is up to 250 micrograms per week, provided that the administration is less frequently than once per day, and wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist comprises at least one of salmeterol, formoterol, bambuterol, or any salt, solvate, or any combination thereof.
14. The method of claim 13 , provided that the lipophilic long-acting selective beta-2 agonist comprises salmeterol, or any salt, solvate, or any combination thereof.
15. The method of claim 13 , provided that the lipophilic long-acting selective beta-2 agonist comprises salmeterol xinafoate.
16. The method of claim 13 , provided that the lipophilic long-acting selective beta-2 adrenergic receptor agonist comprises formoterol fumarate.
17. The method of claim 13 , provided that the lipophilic long-acting selective beta-2 agonist comprises salmeterol, or any salt, solvate, or any combination thereof, in an amount that is up to about 100 micrograms per day administered.
18. The method of claim 13 , provided that the lipophilic long-acting selective beta-2 agonist comprises formoterol, or any salt, solvate, or any combination thereof, in an amount that is up to about 50 micrograms per day administered.